Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia

• Main Authors: Borahm Kim, Woobin Yun, Seung-Tae Lee, Jong Rok Choi, Keon Hee Yoo, Hong Hoe Koo, Chul Won Jung, Sun Hee Kim
• Format: Article
• Language: English
• Published: Nature Publishing Group 2020-08-01
• Series: Scientific Reports
• Online Access: https://doi.org/10.1038/s41598-020-71386-z

Abstract Acute myeloid leukemia (AML) is one of the most common types of leukemia. With the recent advances in sequencing technology and the growing body of knowledge on the genetics of AML, there is increasing concern about cancer predisposing germline mutations as well as somatic mutations. As familial cases sharing germline mutations are constantly reported, germline predisposition gene mutations in patients with AML are gaining attention. We performed genomic sequencing of Korean patients diagnosed with AML to identify the prevalence and characteristics of germline predisposition mutations. Among 180 patients, germline predisposition mutations were identified in 13 patients (13/180, 7.2%, eight adults and five children). Germline mutations of BLM, BRCA1, BRCA2, CTC1, DDX41, ERCC4, ERCC6, FANCI, FANCM, PALB2, and SBDS were identified. Most of the mutations are in genes involved in DNA repair and genomic stability maintenance. Patients harboring germline mutations tended to have earlier onset of AML (p = 0.005), however, the presence of germline mutations did not showed significant association with other clinical characteristics or treatment outcome. Since each mutation was rare, further study with a larger number of cases would be needed to establish the effect of the mutations.